SCHEDULE: Franklin Resources Maintains 14.9% Stake in Benitec Biopharma
Beneficial Ownership Report
Franklin Resources, Inc. and its affiliates report a continued beneficial ownership of 14.9% in Benitec Biopharma Inc., including shares from warrants.
Summary
- Franklin Resources, Inc. and its affiliates, including Franklin Advisers, Inc., beneficially own 4,144,037 shares of Benitec Biopharma Inc. Common Stock.
- This ownership represents 14.9% of the total class of securities.
- The reported beneficial ownership includes 1,554,404 shares of Common Stock that are issuable upon the exercise of warrants.
- Franklin Advisers, Inc. holds sole voting power and sole dispositive power over all 4,144,037 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Benitec Biopharma Inc.
- Two specific funds contribute to this aggregate ownership: Franklin Biotechnology Discovery Fund (a series of Franklin Strategic Series) holds 1,441,568 shares (5.2%), and Franklin Biotechnology Discovery Fund (a sub-fund of Franklin Templeton Investment Funds, a Luxembourg SICAV) holds 2,702,396 shares (9.72%).
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of beneficial ownership and does not contain performance or forward-looking statements about the issuer's operations or financial health.
Future Outlook
NA
Industry Context
This Schedule 13G filing is a routine disclosure of significant ownership by an institutional investor, Franklin Resources, in a biopharmaceutical company. It reflects an ongoing investment position rather than a new strategic move or industry trend, providing transparency on a major shareholder's stake.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a stable large investor base and the continued interest of Franklin Resources and its managed funds in Benitec Biopharma Inc.
Key Dates
| Date | Description |
|---|---|
| 2015-10-13 | Limited Power of Attorney for Franklin Templeton Investment Funds executed. |
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-10-30 | Date of signing of the Schedule 13G Amendment No. 6 by reporting persons. |
Keywords
Benitec Biopharma, Franklin Resources, Franklin Advisers, Schedule 13G, Beneficial Ownership, Common Stock, Biopharma, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.